Number of the records: 1  

Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines

  1. 1.
    SYSNO ASEP0346747
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleInduction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines
    Author(s) Reiniš, Milan (UMG-J) RID
    Štěpánek, Ivan (UMG-J) RID
    Šímová, Jana (UMG-J) RID
    Bieblová, Jana (UMG-J)
    Přibylová, Hana (UMG-J)
    Indrová, Marie (UMG-J) RID
    Bubeník, Jan (UMG-J)
    Source TitleInternational Journal of Oncology. - : Spandidos Publications - ISSN 1019-6439
    Roč. 36, č. 3 (2010), s. 545-551
    Number of pages7 s.
    Languageeng - English
    CountryGR - Greece
    KeywordsMHC class I-deficient tumours ; CpG oligodeoxynucleotides ; human papilloma virus
    Subject RIVEB - Genetics ; Molecular Biology
    R&D ProjectsIAA500520605 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR)
    IAA500520807 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR)
    CEZAV0Z50520514 - UMG-J (2005-2011)
    UT WOS000274718400003
    DOI10.3892/ijo_00000528
    AnnotationWe investigated the efficacy of peptide and peptide-pulsed dendritic cell-based vaccines in a murine model of experimental MHC class I-deficient tumours (TC-1/A9), expressing E6/E7 oncogenes derived from HPV16. Peptide vaccine based on the “short” peptide E749-57 harbouring the CTL epitope and co-administered to the C57BL/6 mice with CpG oligodeoxynucleotide as adjuvant effective against MHC class I-positive but not –deficient tumours, while the “longer” peptide E744-62 (harbouring CTL and Th epitopes)-based vaccines were effective against MHC class I-deficient tumours. Further, we investigated the efficacy of dendritic cells pulsed with either E749-57 or E744-62 peptides. Treatment with dendritic cells pulsed with a “short” peptide resulted in the tumour growth inhibition, albeit weaker as compared to the immunisation with the longer peptide-containing DC. Our data demonstrate that cell-based vaccines can be designed to elicit immunity against MHC class I-deficient tumours.
    WorkplaceInstitute of Molecular Genetics
    ContactNikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217
    Year of Publishing2011
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.